Bill Alpert

The move will modernize legal requirements that have become outdated and costly, SEC Chairman Paul Atkins said.

It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.

Biogen stock fell following a presentation on its experimental Alzheimer’s drug diranersen.

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

A host of companies are competing to bring cancer-detecting blood tests to market.

Grail is awaiting an FDA ruling on a cancer screening test, but already more tests are finding their way into medical practices.

Blue Owl Capital faced higher June-quarter redemption requests than peers, but there was some good news: Exit requests at Blue Owl declined from March quarter levels.

Investors asked to redeem 3% of shares in a Goldman Sachs private credit fund in the June quarter. At other big firms, exit requests reached 17 percent.

Rebecca Slaughter sued the Trump administration, arguing she was wrongly fired from her post at the Federal Trade Commission.

Ares Management limited withdrawals from its Strategic Income Fund after investors sought to redeem 14.4% of shares, though the firm expects to clear its redemption backlog by year-end.

Landlords are competing hard for white collar tenants and spending fairly heavily to offer them attractive spaces.

Swiss asset manager Partners Group caps withdrawals from one of its private-equity funds at 5% of the fund’s value.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

Hamilton Lane says critics misunderstand how private-equity fund stakes are valued, defending the industry’s practice of booking gains on discounted secondary-market purchases.

Investors worry about loans that private-credit funds have made to fund buyouts, but the funds do a lot more than that.

Despite some recent criticism of the firm’s accounting-derived profits, StepStone stock jumped 5.3% Thursday to close at $54.74.

The firm might have to make a whopping payout to its fund managers soon.

The European Systemic Risk Board Advisory is contemplating whether private credit’s recent perturbations merit study, Barron’s has learned.

The fund announced several drastic measures to prop up its stock and return money to shareholders.

With private credit under klieg lights, Apollo Global Management is telling investors not to heed negative headlines about that market.